Showing 1–6 of 6 results
-
Research |
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- Khyati N. Shah
- , Roma Bhatt
- , Julia Rotow
- , Julia Rohrberg
- , Victor Olivas
- , Victoria E. Wang
- , Golzar Hemmati
- , Maria M. Martins
- , Ashley Maynard
- , Jonathan Kuhn
- , Jacqueline Galeas
- , Hayley J. Donnella
- , Swati Kaushik
- , Angel Ku
- , Sophie Dumont
- , Gregor Krings
- , Henry J. Haringsma
- , Liliane Robillard
- , Andrew D. Simmons
- , Thomas C. Harding
- , Frank McCormick
- , Andrei Goga
- , Collin M. Blakely
- , Trever G. Bivona
- & Sourav Bandyopadhyay
-
Research |
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- Robert J. Nichols
- , Franziska Haderk
- , Carlos Stahlhut
- , Christopher J. Schulze
- , Golzar Hemmati
- , David Wildes
- , Christos Tzitzilonis
- , Kasia Mordec
- , Abby Marquez
- , Jason Romero
- , Tientien Hsieh
- , Aubhishek Zaman
- , Victor Olivas
- , Caroline McCoach
- , Collin M. Blakely
- , Zhengping Wang
- , Gert Kiss
- , Elena S. Koltun
- , Adrian L. Gill
- , Mallika Singh
- , Mark A. Goldsmith
- , Jacqueline A. M. Smith
- & Trever G. Bivona
-
Research | | Open
-
Research |
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- Luping Lin
- , Amit J Sabnis
- , Elton Chan
- , Victor Olivas
- , Lindsay Cade
- , Evangelos Pazarentzos
- , Saurabh Asthana
- , Dana Neel
- , Jenny Jiacheng Yan
- , Xinyuan Lu
- , Luu Pham
- , Mingxue M Wang
- , Niki Karachaliou
- , Maria Gonzalez Cao
- , Jose Luis Manzano
- , Jose Luis Ramirez
- , Jose Miguel Sanchez Torres
- , Fiamma Buttitta
- , Charles M Rudin
- , Eric A Collisson
- , Alain Algazi
- , Eric Robinson
- , Iman Osman
- , Eva Muñoz-Couselo
- , Javier Cortes
- , Dennie T Frederick
- , Zachary A Cooper
- , Martin McMahon
- , Antonio Marchetti
- , Rafael Rosell
- , Keith T Flaherty
- , Jennifer A Wargo
- & Trever G Bivona
-
Research |
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
- Gorjan Hrustanovic
- , Victor Olivas
- , Evangelos Pazarentzos
- , Asmin Tulpule
- , Saurabh Asthana
- , Collin M Blakely
- , Ross A Okimoto
- , Luping Lin
- , Dana S Neel
- , Amit Sabnis
- , Jennifer Flanagan
- , Elton Chan
- , Marileila Varella-Garcia
- , Dara L Aisner
- , Aria Vaishnavi
- , Sai-Hong I Ou
- , Eric A Collisson
- , Eiki Ichihara
- , Philip C Mack
- , Christine M Lovly
- , Niki Karachaliou
- , Rafael Rosell
- , Jonathan W Riess
- , Robert C Doebele
- & Trever G Bivona
-
Research |
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- Zhenfeng Zhang
- , Jae Cheol Lee
- , Luping Lin
- , Victor Olivas
- , Valerie Au
- , Thomas LaFramboise
- , Mohamed Abdel-Rahman
- , Xiaoqi Wang
- , Alan D Levine
- , Jin Kyung Rho
- , Yun Jung Choi
- , Chang-Min Choi
- , Sang-We Kim
- , Se Jin Jang
- , Young Soo Park
- , Woo Sung Kim
- , Dae Ho Lee
- , Jung-Shin Lee
- , Vincent A Miller
- , Maria Arcila
- , Marc Ladanyi
- , Philicia Moonsamy
- , Charles Sawyers
- , Titus J Boggon
- , Patrick C Ma
- , Carlota Costa
- , Miquel Taron
- , Rafael Rosell
- , Balazs Halmos
- & Trever G Bivona
